Zealand Pharma has suffered another setback in its bid to bring glucagon receptor agonist ... rescue therapy for diabetics. Eli Lilly's nasal spray Baqsimi was also approved in 2019 for a similar ...

It received priority review ... nasal spray/powder, cataplasms, implants and foam. Of these, there were eight paediatric drugs, including amlodipine besilate for suspension, glucagon nasal powder ...

State of Alaska Department of Revenue lessened its holdings in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH – Free Report) by 1.6% in the fourth quarter, HoldingsChannel reports. The fund owned 21,325 ...

Note: After the Food and Drug Administration (FDA) approves a drug, it tracks and reviews side effects of ... Baqsimi is a nasal spray. It’s given as one spray into one nostril during an episode ...

The FDA has accepted for review the NDA for bumetanide nasal spray for edema associated with CHF, as well as hepatic and renal disease.

The table below is a review of notable updates that occurred in January 2025 for investigational products in development.

A Prescription Drug User Fee Act target date of September 14, 2025 has been assigned to the application. The Food and Drug Administration (FDA) has accepted for review the New Drug Application ...

Here’s our detailed review of its services, pricing, advantages, and drawbacks. While widely known for its male health offerings, Ro has more recently added glucagon-like peptide-1 (GLP-1 ...

The global landscape of neurological health is undergoing a transformative moment with a pioneering nasal spray that could potentially revolutionize Alzheimer‘s disease management. As ...

Nasal spray is being recalled over microbial failure. The U.S. Food and Drug Administration shared information about the recall affecting NeilMed Pharmaceuticals’ NasoGel Spray, last week.

The drug is designed to reduce inflammation in the brain and has been used on MS, cancer and migraine headaches.